Comparative Review of Approved Melatonin Agonists for the Treatment of Circadian Rhythm Sleep-Wake Disorders

被引:76
作者
Williams, Wilbur P. , III [1 ]
McLin, Dewey E., III [1 ]
Dressman, Marlene A. [2 ]
Neubauer, David N. [3 ]
机构
[1] Vanda Pharmaceut Inc, Dept Med Affairs, Washington, DC USA
[2] Vanda Pharmaceut Inc, Dept Clin Dev, Washington, DC USA
[3] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA
来源
PHARMACOTHERAPY | 2016年 / 36卷 / 09期
关键词
melatonin agonists; sleep drug effects; circadian rhythm; drug effects; PHASE RESPONSE CURVE; STRUCTURAL-CHARACTERIZATION; ABSOLUTE BIOAVAILABILITY; SUPRACHIASMATIC NUCLEUS; COMMERCIAL PREPARATIONS; SHIFT WORK; RAMELTEON; RECEPTORS; CONTAMINANTS; MULTICENTER;
D O I
10.1002/phar.1822
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Circadian rhythm sleep-wake disorders (CRSWDs) are characterized by persistent or recurrent patterns of sleep disturbance related primarily to alterations of the circadian rhythm system or the misalignment between the endogenous circadian rhythm and exogenous factors that affect the timing or duration of sleep. These disorders collectively represent a significant unmet medical need, with a total prevalence in the millions, a substantial negative impact on quality of life, and a lack of studied treatments for most of these disorders. Activation of the endogenous melatonin receptors appears to play an important role in setting the circadian clock in the suprachiasmatic nucleus of the hypothalamus. Therefore, melatonin agonists, which may be able to shift and/or stabilize the circadian phase, have been identified as potential therapeutic candidates for the treatment of CRSWDs. Currently, only one melatonin receptor agonist, tasimelteon, is approved for the treatment of a CRSWD: non-24-hour sleep-wake disorder (or non-24). However, three additional commercially available melatonin receptor agonists-agomelatine, prolonged-release melatonin, and ramelteon-have been investigated for potential use for treatment of CRSWDs. Data indicate that these melatonin receptor agonists have distinct pharmacologic profiles that may help clarify their clinical use in CRSWDs. We review the pharmacokinetic and pharmacodynamic properties of these melatonin agonists and summarize their efficacy profiles when used for the treatment of CRSWDs. Further studies are needed to determine the therapeutic potential of these melatonin agonists for most CRSWDs.
引用
收藏
页码:1028 / 1041
页数:14
相关论文
共 67 条
[1]   PLASMA-CONCENTRATIONS OF MELATONIN IN MAN FOLLOWING ORAL ABSORPTION OF DIFFERENT PREPARATIONS [J].
ALDHOUS, M ;
FRANEY, C ;
WRIGHT, J ;
ARENDT, J .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1985, 19 (04) :517-521
[2]  
American Academy of Sleep Medicine, 2014, The International Classification of Sleep Disorders
[3]  
[Anonymous], EMEAHC695
[4]  
[Anonymous], CLIN PHARM THER
[5]  
[Anonymous], CIRC 2 MG PROL REL T
[6]  
[Anonymous], HETLIOZ TAS CAPS OR
[7]  
[Anonymous], 2007, COLD SPRING HARB SYM, DOI DOI 10.1101/sqb.2007.72.064
[8]  
[Anonymous], HETL SUMM PROD CHAR
[9]  
[Anonymous], EMEA6552512008
[10]  
[Anonymous], ROZ RAM TABL PACK IN